SEATTLE, Oct. 25 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq:
ZGEN) announced today that it will report third quarter 2007 financial
results on Wednesday, October 31, 2007. Members of the company's senior
management will discuss the results and provide a general corporate update
in a conference call and webcast on Wednesday, October 31, 2007 at 10:30
a.m. Eastern Time.

The ZymoGenetics Q3 2007 Financial Results Conference Call may be
accessed on October 31 by dialing 877-407-0782. The international dial in
number is 201-689-8567. Participants should dial in to the call
approximately 10 minutes prior to the scheduled start time to register. The
webcast can be accessed at http://www.zymogenetics.com and will be archived
for 30 days.

ZymoGenetics creates novel protein drugs with the potential to
significantly help patients fight their diseases. The Company is developing
a diverse pipeline of product candidates that are moving into and through
clinical development. These candidates span a wide array of clinical
opportunities that include bleeding, autoimmune diseases and cancer.
ZymoGenetics intends to commercialize these product candidates through
internal development, collaborations with partners, and out-licensing of
patents from its extensive patent portfolio. For further information, visit
http://www.zymogenetics.com.

This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on the current intent and expectations
of the management of ZymoGenetics. These statements are not guarantees of
future performance and involve risks and uncertainties that are difficult
to predict. ZymoGenetics' actual results and the timing and outcome of
events may differ materially from those expressed in or implied by the
forward-looking statements because of risks associated with our unproven
discovery strategy, preclinical and clinical development, regulatory
oversight, intellectual property claims and litigation and other risks
detailed in the company's public filings with the Securities and Exchange
Commission, including the company's Annual Report on Form 10-K for the year
ended December 31, 2006. Except as required by law, ZymoGenetics undertakes
no obligation to update any forward-looking or other statements in this
press release, whether as a result of new information, future events or
otherwise.

(Date:8/16/2017)... -- This year,s edition of the Inc. 5000 features a now-familiar name: BioPoint ... made the list for the third year in a row. Now in ... based on a set of quantitative metrics. In addition, BioPoint was also ... the Bay State . ... Inc. 5000 ...

(Date:8/15/2017)... ... 15, 2017 , ... The Conference Forum and The Trout ... a series of upcoming panels and events. The partnership culminates with the 4th ... in New York City. , “With our experience in producing the Immuno-Oncology 360° NYC ...

(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...